Mar 14 |
Eton Pharmaceuticals GAAP EPS of -$0.09 misses by $0.05, revenue of $7.3M misses by $0.36M
|
Mar 14 |
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
|
Mar 14 |
Earnings Scheduled For March 14, 2024
|
Mar 13 |
Eton Pharmaceuticals Q4 2023 Earnings Preview
|
Mar 1 |
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
|
Feb 29 |
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
|
Feb 26 |
Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?
|
Feb 21 |
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
|
Feb 19 |
Individual investors account for 59% of Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) ownership, while institutions account for 18%
|
Feb 2 |
Eton announces commercial availability of Nitisinone capsules
|